MPO and lung carcinoma: As compared to pre-RFA (median value, 429.6 U/ml; range, 219.4–786.9), there was a significantly enhanced MPO activity in post-RFA lung cancer patients (median value, 1519.4 U/ml; range, 920.1–2336.2; Figure 2).